|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Youngsaye, W, Hartland, CL, Morgan, BJ, Ting, A, Nag, PP, Vincent, B, Mosher, CA, Bittker, JA, Dandapani, S, Palmer, M, Whitesell, L, Lindquist, S, Schreiber, SL, Munoz, B|
|Journal||Beilstein journal of organic chemistry|
The National Institutes of Health Molecular Libraries and Probe Production Centers Network (NIH-MLPCN) screened >300,000 compounds to evaluate their ability to restore fluconazole susceptibility in resistant Candida albicans isolates. Additional counter screens were incorporated to remove substances inherently toxic to either mammalian or fungal cells. A substituted indazole possessing the desired bioactivity profile was selected for further development, and initial investigation of structure-activity relationships led to the discovery of ML212.